Literature DB >> 12894524

The thioredoxin-thioredoxin reductase system: over-expression in human cancer.

David T Lincoln1, Eman M Ali Emadi, Kathryn F Tonissen, Frank M Clarke.   

Abstract

Redox control has emerged as a fundamental biological control mechanism. One of the major redox control systems is the thioredoxin system comprised of thioredoxin (TRX) and thioredoxin reductase (TR). Together they form a powerful system involved in many central intracellular and extracellular processes including cell proliferation, the redox regulation of gene expression and signal transduction, protection against oxidative stress, anti-apoptotic functions, growth factor and co-cytokine effects, and regulation of the redox state of the extracellular environment. Over recent years this system has increasingly been linked to the development and expression of cancer phenotypes. In this report immunocytochemical approaches have been used to simultaneously determine the expression and localisation of both TRX and TR in primary human cancers, including breast cancer, thyroid, prostate and colorectal carcinoma, and malignant melanoma. In aggressive invasive mammary carcinomas and advanced malignant melanomas, thioredoxin was highly over-expressed compared to tumours of lesser aggressive nature. TRX expression was found in both nuclear and cytoplasmic location in the neoplastic cells. Furthermore, increased levels of TRX positively correlate with thioredoxin reductase (TR) expression and localisation. These results, which are the first immunocytochemical studies on the in vivo expression and localisation of TRX and TR in melanomas, thyroid, prostate and colorectal carcinomas and the first reports of TR expression in breast carcinomas, significantly extend the range of human cancers for which such data is available. Overall the results support the conclusion that aggressive tumours greatly over-express both TRX and TR. Such tumours have a high proliferation capacity, a low apoptosis rate and an elevated metastatic potential strongly implicating the involvement of the TRX system in the processes of oncogenesis and tumourogenesis and confirming its potential as a target for anticancer therapy for a wide range of human tumours.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12894524

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  89 in total

1.  Upregulation of connexin43 contributes to PX-12-induced oxidative cell death.

Authors:  Gang Li; Kun Gao; Yuan Chi; Xiling Zhang; Takahiko Mitsui; Jian Yao; Masayuki Takeda
Journal:  Tumour Biol       Date:  2015-12-18

2.  Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism.

Authors:  Ryuta Tobe; Min-Hyuk Yoo; Noelia Fradejas; Bradley A Carlson; Soledad Calvo; Vadim N Gladyshev; Dolph L Hatfield
Journal:  Biochem J       Date:  2012-08-01       Impact factor: 3.857

3.  Serum selenium and risk of prostate cancer-a nested case-control study.

Authors:  Ulrike Peters; Charles B Foster; Nilanjan Chatterjee; Arthur Schatzkin; Douglas Reding; Gerald L Andriole; E David Crawford; Stefan Sturup; Stephen J Chanock; Richard B Hayes
Journal:  Am J Clin Nutr       Date:  2007-01       Impact factor: 7.045

4.  Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development.

Authors:  Cemile Jakupoglu; Gerhard K H Przemeck; Manuela Schneider; Stéphanie G Moreno; Nadja Mayr; Antonis K Hatzopoulos; Martin Hrabé de Angelis; Wolfgang Wurst; Georg W Bornkamm; Markus Brielmeier; Marcus Conrad
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

5.  Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

Authors:  Stefanie Prast-Nielsen; Thomas S Dexheimer; Lena Schultz; William C Stafford; Qing Cheng; Jianqiang Xu; Ajit Jadhav; Elias S J Arnér; Anton Simeonov
Journal:  Free Radic Biol Med       Date:  2011-01-22       Impact factor: 7.376

Review 6.  Anti-cancer activity of new designer hydrogen sulfide-donating hybrids.

Authors:  Khosrow Kashfi
Journal:  Antioxid Redox Signal       Date:  2013-06-07       Impact factor: 8.401

Review 7.  Toward understanding success and failures in the use of selenium for cancer prevention.

Authors:  Holger Steinbrenner; Bodo Speckmann; Helmut Sies
Journal:  Antioxid Redox Signal       Date:  2013-03-21       Impact factor: 8.401

8.  Clinical Significance of the Thioredoxin System and Thioredoxin-Domain-Containing Protein Family in Hepatocellular Carcinoma.

Authors:  Sang Yeon Cho; Sungha Kim; Mi-Ju Son; Woo Sun Rou; Seok Hyun Kim; Hyuk Soo Eun; Byung Seok Lee
Journal:  Dig Dis Sci       Date:  2018-10-04       Impact factor: 3.199

9.  Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.

Authors:  Yasmine Amitay; Hilary Shmeeda; Yogita Patil; Jenny Gorin; Dina Tzemach; Lidia Mak; Patricia Ohana; Alberto Gabizon
Journal:  Pharm Res       Date:  2015-11-16       Impact factor: 4.200

10.  Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues.

Authors:  Carol D Curtis; Daniel L Thorngren; Ann M Nardulli
Journal:  BMC Cancer       Date:  2010-01-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.